NEW YORK (GenomeWeb News) – GenMark Diagnostics said after the close of the market Monday that it has lowered its annual revenue guidance to approximately $30 million from its previous expectation of $35 million.
Registering provides access to this and other free content.
Already have an account?Login Now.
In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.
Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.
Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.
Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.